Capricor Therapeutics Inc (CAPR)
5.64
+0.31
(+5.82%)
USD |
NASDAQ |
May 16, 16:00
5.75
+0.11
(+1.95%)
After-Hours: 20:00
Capricor Therapeutics Research and Development Expense (Annual): 36.45M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 36.45M |
| December 31, 2022 | 21.82M |
| December 31, 2021 | 13.57M |
| December 31, 2020 | 8.457M |
| December 31, 2019 | 5.142M |
| December 31, 2018 | 12.07M |
| December 31, 2017 | 10.77M |
| December 31, 2016 | 16.04M |
| December 31, 2015 | 13.76M |
| Date | Value |
|---|---|
| December 31, 2014 | 7.787M |
| December 31, 2013 | 5.197M |
| December 31, 2012 | 2.634M |
| December 31, 2011 | 4.137M |
| December 31, 2010 | 4.081M |
| December 31, 2009 | 4.466M |
| December 31, 2008 | 9.478M |
| December 31, 2007 | 5.124M |
| December 31, 2006 | 2.700M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
5.142M
Minimum
2019
36.45M
Maximum
2023
17.09M
Average
13.57M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Sarepta Therapeutics Inc | 877.39M |
| PTC Therapeutics Inc | 666.56M |
| Solid Biosciences Inc | 76.56M |
| Cutera Inc | 21.41M |
| Catalyst Pharmaceuticals Inc | 93.15M |